Bone: IGFBP1—hepatokine and target for FGF21-mediated bone loss

@article{Phillips2015BoneIA,
  title={Bone: IGFBP1—hepatokine and target for FGF21-mediated bone loss},
  author={Robert F. Phillips},
  journal={Nature Reviews Endocrinology},
  year={2015},
  volume={11},
  pages={690-690}
}
Insulin-like growth factor-binding protein 1 (IGFBP1) has been identified as a hormone that is produced in the liver and promotes osteoclastogenesis and bone resorption, in a new study published in Cell Metabolism. IGFBP1 blockade is now a target for the treatment of conditions such as osteoporosis, and could enable inhibition of bone loss mediated by fibroblast growth factor 21 (FGF21; a potential therapeutic agent for diabetes mellitus), without inhibiting insulin sensitivity. Wang and co… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS